COVID-19-Associated Acute Transverse Myelitis: A Case Series of a Rare Neurologic Condition

Liaquat Ali 1, 2, Imran Mohammed 3, Yasin Zada 3, Haya Salem 4, Ambreen Iqrar 1

1. Neurology, Hamad General Hospital, Doha, Qatar. 2. Neurology, Weill Cornell Medicine-Qatar, Doha, Qatar. 3. Internal Medicine, Hamad General Hospital, Doha, Qatar. 4. Medicine, College of Medicine, Qatar University, Doha, Qatar

Corresponding author: Liaquat Ali, lali5@hamad.qa

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection is not confined to the respiratory system, but has also shown extra-pulmonary invasion including the nervous system. About 36.4% of hospitalized patients in China with confirmed coronavirus disease 2019 (COVID-19) infection had neurological manifestations. SARS-CoV-2 virus enters the human body through angiotensin converting enzyme-2 (ACE-2) receptors on the surface of human cells and causes disease. ACE2 receptors are also expressed on the surface of spinal cord cells. More rare neurologic conditions have been reported in the literature to be associated with COVID-19 such as acute transverse myelitis (ATM), Guillain Barre syndrome, acute flaccid myelitis, etc. We report two cases of confirmed COVID-19 who presented four to five days of their COVID-19 symptoms and progressive bilateral lower limb weakness and urinary retention.

ATM is an acquired spinal cord disorder. ATM is a relatively common neurological complication of COVID-19, accounting for 1.2% of all neurological complications associated with COVID-19. The mechanism by which COVID-19 causes ATM is not completely understood but has been assumed to be due to the structural resemblance of RNA viruses. Entrance of SARS-CoV-2 to the nervous system can take place through two pathways, either directly or indirectly. The direct pathway is through trans-synaptic transmission from the peripheral nervous system or by hematogenous spread into the blood-brain barrier through ACE-2, while the indirect pathway is through a systemic immune response.

Introduction

Since the revelation of coronavirus disease 2019 (COVID-19) globally from Wuhan, China, the infection has progressively evolved in presentation. We now know that the viral infection is not confined to the respiratory system, through which it is transmitted, but has also shown extra-pulmonary invasion including the nervous system at different stages of the infection course. The most common neurological symptoms in COVID-19 patients are anosmia, myalgia, headache, altered mental status or brain fog. About 36.4% of hospitalized patients in China with confirmed COVID-19 infection had neurological manifestations [1]. The same study also revealed that patients with a more severe infection were more likely to develop neurological manifestations. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters the human body through angiotensin converting enzyme-z (ACE-2) receptors on the surface of human cells and causes disease [2,3]. ACE2 receptors are also expressed on the surface of spinal cord cells; whether spinal cord neurons are concerned in COVID-19 is still unknown [4,5]. A spectrum of neuroimaging abnormalities has been described in patients with COVID-19, the most common of which are acute ischemic stroke, cortical FLAIR signal abnormality, cerebral microbleeds, leptomeningeal enhancement, cytotoxic lesions in the splenium of the corpus callosum and other manifestations of encephalitis [6].

More rare neurologic conditions have also been reported in the literature to be associated with COVID-19 such as cerebrovascular accidents, acute transverse myelitis (ATM), Guillain Barre syndrome (GBS), acute flaccid myelitis, acute encephalitis, acute disseminated encephalomyelitis (ADEM), generalized myoclonus and posterior reversible encephalopathy syndrome (PRES) [7]. In this case series, we present peculiar neurological complications of COVID-19-related ATM in patients who were admitted to the COVID-19 facility, Tertiary Care Hospital, Hamad Medical Cooperation in Doha, Qatar.

Case Presentation

Case 1

A 56-year-old gentleman, known to have type 2 diabetes mellitus for four years and newly discovered G6PD deficiency, came to the emergency department (ED) with complaints of high-grade fever, fatigue for four days, lower limbs weakness and urinary retention for one day. He reported no contact with COVID-19-positive or other sick patients. On presentation to the emergency department, he was febrile with a...
temperature of 38.9°C, normal respiratory rate and oxygen saturation were 96% at room air. Physical examination revealed lower abdominal tenderness, palpable urinary bladder, bilateral lower limbs weakness of 3/5 medical research council (MRC) grades for muscle strength and numbness. Foley’s catheter was inserted which drained more than a liter of urine in the urinary bag. Ultrasound kidney, ureter and bladder (KUB) was performed to rule out obstructive uropathy that showed distended urinary bladder, pre-void urine volume of 1327ml, post-void 873ml. Chest X-ray showed evolving consolidation in the right lower zone and perihilar extending to the periphery and bilateral prominent broncho-vascular marking (Figure 1).

**FIGURE 1: Chest x-ray (PA view)**

Chest x-ray showed right side lower zone evolving consolidation, extending to periphery and perihilar regions.

The patient was admitted to the medical floor for evaluation of fever and suspected COVID-19. After 12 hours of admission, the patient became tachypneic and hypoxic with a respiratory rate of 36 breaths/minute and pulse oximetry oxygen saturation drop to 92% at room air. COVID-19 PCR sample obtained from both nasopharynx and throat of the patient was positive for SARS-CoV-2 infection. He was diagnosed with COVID-19 pneumonia. He was transferred to COVID-19 tertiary care hospital for further evaluation and treatment. The neurology team was consulted for evaluation of lower limbs weakness. Neurological examination showed normal higher mental function. All cranial nerves included facial nerve and extraocular muscles movements were intact and full range. Motor system examination of upper limbs showed good muscle bulk, normal tone and muscles strength, while the lower limb examination revealed reduced muscles tone, muscles strength of 3/5 (MRC) distal and proximal bilaterally. Reflexes were no response (deep tendon reflexes grade of 0) at knee and ankle reflexes and equivocal plantar response. There were impairment of sensation of lower limbs bilateral with a sensory level at T6 (at xiphoid process). MRI Head and Spine with gadolinium of T2 weighted images of the sagittal and axial spine demonstrate subtle high signal intensity in the ventral horn of the grey matter in the upper and mid thoracic cord, without post gadolinium contrast enhancement; findings represent viral transverse myelitis related to COVID-19 infection (as shown by red arrows in Figure 2 [sagittal view] and Figure 3 [axial view]).
FIGURE 2: MRI spine with gadolinium

Magnetic resonance imaging (MRI) with gadolinium T2 weighted images of the cervicothoracic spine showed subtle high signal intensity in the ventral horn of the grey matter in the upper and mid thoracic cord, without post IV contrast enhancement (red arrow head).

FIGURE 3: MRI cervicothoracic spine with gadolinium.

MRI cervicothoracic spine T2 weighted images of the axial view with gadolinium showed hyperintensity signals in the ventral horn of the grey matter in the upper and mid thoracic cord without enhancement (red arrow head).

Lumbar puncture was performed which showed cerebrospinal fluid (CSF) pleocytosis with lymphocyte predominant, normal glucose and high protein, Mycobacterium tuberculosis (MTB) PCR and herpes simplex virus (HSV) PCR were negative (Table 1). Other laboratory results that were performed during admission are tabulated in Table 2 including negative autoimmune immunological tests.
| CSF analysis                        | Results                      | Reference range               |
|------------------------------------|------------------------------|-------------------------------|
| Appearance                         | Clear                        |                               |
| White Cell count                   | 152 (89% lymphocytes)        | (0-5 /uL)                     |
| Protein                            | 0.54 gm/L                    | (0.15 – 0.45 gm/L)            |
| Albumin                            | 400 (high)                   | (0-350mg/L)                   |
| Glucose                            | 4.69 mmol/L                  | (2.22 – 3.89 mmol/L)          |
| Viral meningitis PCR panel (include HSV1,2) | Negative                  |                               |
| Gram stain and culture             | Negative                     |                               |
| CSF Cryptococcal antigen           | Negative                     |                               |
| CSF gram stain/cultures            | No growth                    |                               |
| CSF MTB -PCR                       | Negative                     |                               |

TABLE 1: Cerebrospinal fluid analysis and cultures

Lumbar puncture was performed showed of cerebrospinal fluid (CSF) pleocytosis with lymphocyte predominant, normal glucose and high protein.

MTB: Mycobacterium tuberculosis, HSV: herpes simplex virus
| Test                   | Result (Reference range) |
|-----------------------|--------------------------|
| White blood cell      | 10.2 (3.5-9.5×10^9/L)    |
| Hemoglobin            | 10.6 (13.5-17.5g/dL)     |
| INR                   | 1.1 (<1.1)               |
| creatinine            | 61 (44-110umol/L)        |
| Prothrombin time      | 14 (11 to 13.5 sec)      |
| Sodium                | 135 (135-149 meq/L)      |
| ALT                   | 62 (5-40 U/L)            |
| AST                   | 125 (5-40 U/L)           |
| C-reactive protein    | 78 (0-5mg/L)             |
| Ferritin              | 435 (30-553 ug/L)        |
| Interleukin-6 (IL-6)  | 97 (high) (≤ 7 pg/mL)    |
| D-Dimer               | 23.5 (0.0-0.49 mg/L FEU) |
| HbA1c                 | 5.7%                     |
| S HSV IgG/M           | Negative                 |
| ANA                   | Negative                 |
| ANCA                  | Negative                 |
| TSH                   | 0.47(normal)             |
| COVID-19 PCR          | Positive                 |
| Vit B12 level         | 109 low (145-595pmol/L)  |
| Troponin –T hs        | 63 high (3-15 ng/L)      |
| Blood culture         | No growth                |

**TABLE 2: Routine blood Investigations.**

Blood lab Investigations done at the Emergency Department.

INR: international normalized ratio, ALT: alanine transaminase, AST: aspartate transaminase, HbA1c: hemoglobin A1c, HSV: herpes simplex virus, ANA: antinuclear antibodies, ANCA: antineutrophil cytoplasmic antibodies, TSH: thyroid stimulating hormone

After 48 hours of admission, the patient’s inflammatory markers were noted to be elevated with high c-reactive protein (CRP), D-dimer, ferritin, interleukin-6, troponin T, alanine transaminase (ALT) and aspartate transaminase (AST) as shown in Table 2. Based on the presenting symptoms, physical examination, MRI of spine and laboratory results of acute weakness of lower limbs, urinary retention, an abnormal sensory level at T6, abnormal CSF study and abnormal MRI of the spinal cord which demonstrated high signal intensity in the upper and mid-thoracic cord, findings were suggestive of the diagnosis of acute transverse myelitis, most likely related to COVID-19. The patient was treated with intravenous pulse methylprednisolone 1 gram daily for five days and acyclovir 10 mg/kg three times for 14 days. On the fourth day of admission in the COVID-19 facility, the patient collapsed and went into cardiac arrest. Immediate cardiopulmonary resuscitation was initiated. After a few cycles of resuscitation return of spontaneous circulation was achieved but the patient remained unconscious. Bedside "point of care" ultrasound exam (POCUS) showed right atrial and ventricle (RA/RV) dilatation. A massive unstable pulmonary embolism was suspected as the cause of cardiac arrest and he was treated with thrombolytic therapy. Despite this the patient deteriorated and unfortunately passed away.

**Case 2**

A 43-year-old gentleman, newly diagnosed with diabetes mellitus and not previously vaccinated for COVID-19, was referred to the Emergency Department (ED) with a five-day history of fever, sore throat, headache, and generalized body ache. He denied any history of sick contacts. He was found to be positive for COVID-19
reverse transcription polymerase chain reaction (RT-PCR) test from nasopharyngeal and oropharyngeal swabs. Upon arrival at the ED, his chest x-ray showed multiple airspace heterogenous opacities in both lower and peripheral lung fields (Figure 4).

![Chest X-ray (case 2)](image)

**FIGURE 4: Chest X ray (case 2)**

Chest X-ray showed multiple airspace heterogenous opacities in both lung fields especially lower and peripheral lung zones (red arrow head).

His highest body temperature recorded in the ED was 39.4 F. Two hours after admission, the patient complained of sudden onset bilateral lower limb numbness and weakness, inability to sit, and difficulty passing urine with intermittent urinary dribbling. The weakness was isolated to his lower limbs and was symmetrical. He had no history of spinal trauma.

On physical examination, the patient vital signs were stable; oxygen saturation was 98% on room air. Neurological examination revealed intact higher function, cranial nerve and upper limbs tests. Meanwhile, on examination of the lower limbs, the patient was paraplegia, MRC muscle power of 0/5 that is symmetric proximally and distally - with pronounced hypotonia bilaterally along with symmetrical loss of pinprick sensation below the level of T10, proprioception hypesthesia, and hyporeflexia at the knee and ankle. Additionally, the patient had suprapubic tenderness with a palpable bladder and loss of anal tone. Insertion of foley catheters in the ED yielded more than 600 ml of urine. Magnetic resonance imaging (MRI) of the head and spine were ordered. MRI of the head with gadolinium was unremarkable and ruled out brain structural or demyelinating disease, while MRI of the spine with gadolinium showed longitudinally extensive abnormal cord signaling extending from cervical C-2 to thoracic T-11 vertebral level without enhancement or haemorrhage or no diffusion restriction and normal appearance of conus medullaris and cauda equina nerve roots (Figure 5, Figure 6).
FIGURE 5: MRI cervicothoracic spine with gadolinium.

MRI of the cervicothoracic spine T2 weighted images sagittal view showed extensive intramedullary abnormal cord signaling extending from cervical C-2 to thoracic T-11 vertebral level without post contrast enhancement.

FIGURE 6: MRI cervicothoracic spine with gadolinium.

MRI of the spine cervicothoracic spine T2 weighted axial view showed intramedullary extensive abnormal cord signaling extending from cervical C2 to thoracic T11 vertebral level (as shown in 6A), and T1 weighted sagittal view with post gadolinium without post contrast enhancement (as shown in 6B).

Cerebrospinal fluid (CSF) analysis showed pleocytosis with predominantly neutrophils with elevated protein and glucose levels and negative oligoclonal bands. Bacterial and tuberculosis cultures showed no growth and viral PCR meningitis panel, MTB-PCR of the CSF was negative (Table 3).
| CSF analysis                              | Results                  | Reference range                  |
|------------------------------------------|--------------------------|---------------------------------|
| Appearance                               | Clear                    |                                 |
| White Cell count                         | 186 (85% neutrophils)    | (0-5 /µL)                       |
| Protein                                  | 1.25 g/mL                | (0.15 – 0.45 g/mL)              |
| Albumin                                  | 715 (high)               | (0-350mg/L)                     |
| Glucose                                  | 9.16 mmol/L              | (2.22 – 3.89 mmol/L)            |
| Viral meningitis PCR panel (include HSV1,2) | Negative               |                                 |
| Gram stain and culture                   | Negative                 |                                 |
| Oligoclonal bands                        | Negative                 |                                 |
| CSF-IgG                                  | 208 (high)               | (0-34g/mL)                      |
| Cryptococcal antigen                     | Negative                 |                                 |
| IgG index                                | 0.6                      | (0.3-to-0.6)                    |
| CSF MTB-PCR                              | Negative                 |                                 |

**TABLE 3: Cerebrospinal fluid analysis and cultures.**

Cerebrospinal fluid (CSF) analysis showed predominantly neutrophilic pleocytosis with elevated CSF protein and glucose and negative oligoclonal bands, bacterial antigens and cultures showed no growth and viral PCR meningitis panel of the CSF was negative including HSV 1, 2.

MTB: Mycobacterium tuberculosis, HSV: herpes simplex virus

Other laboratory results that were performed during admission are tabulated in Table 4, including negative autoimmune immunological tests.
| Test                  | Result               | Reference range                  |
|----------------------|----------------------|----------------------------------|
| White blood cell     | 10.8 with anc of 8%  | (3.5 to 9.5 x 10^9/L)            |
| Hemoglobin           | 14.8                | (13.5 to 17.5 gm/dl)             |
| INR                  | 1.2                 | (0.8 to 1.1)                     |
| Urea                 | 3.3                 | (2.1 to 8.5 mmol/l)              |
| Prothrombin time     | 14.3                | (11 to 13.5 seconds)             |
| Sodium               | 135                 | (135 to 149 meq/l)               |
| C-reactive protein   | 36.1                | (8 to 10 mg/l)                   |
| Ferritin             | 338                 | (24 to 336 mg/l)                 |
| HbA1c                | 11.4%               | (4 to 5.6%)                      |
| Random blood sugar   | 15.3 mmol/L         | (7.8 to 11 mmol/L)               |
| ANA                  | Negative            |                                  |
| ANCA                 | Negative            |                                  |
| Anti-Ro/La           | Negative            |                                  |
| COVID-19 PCR         | Positive (CT=24.38) |                                  |
| Vit B12 level        | 291                 | (145-595 pg/ml)                  |

**TABLE 4: Blood lab Investigations.**

Other blood laboratory results that were performed during admission, including negative autoimmune immunological tests.

INR: international normalized ratio, HbA1c: hemoglobin A1c, ANA: antinuclear antibodies, ANCA: antineutrophil cytoplasmic antibodies

---

Based on clinical and radiological findings the patient was diagnosed with para-infectious long extensive transverse myelitis secondary to symptomatic COVID-19 infection.

The patient was treated with intravenous pulse methylprednisolone 1 gm daily for five days. Adjacently, the patient received five days of IV immunoglobulin (0.4g/kg) and extensive physiotherapy. Post-treatment, the patient did not show any clinical improvement, therefore, MRI of the spine was repeated which showed substantial interval regression in radiological findings with minimal residual abnormal signal intensity seen in the mid dorsal region from T5 to T9. No definite diffusion restriction or focal enhancing lesion (Figure 7).
As a result, the team decided to begin five sessions of plasmapheresis and refer the patient for rehabilitation therapy afterwards. During his admission, there was no improvement in the patient’s paraplegia. He was transferred to a rehabilitation center for intensive physiotherapy where he stayed for two and half months. At the time of discharge examination from the rehabilitation center, although there was an improvement in overall functional status like sitting balance, independent bed mobility, improvement in lower limb spasticity but the sensations in lower limbs remained absent with power in lower limbs graded as 0/5 and neurogenic bladder. He was dependent on a self-propelled wheelchair for mobility. At this point, the patient was discharged to his country with advice to continue the rehabilitation program.

Discussion

Acute transverse myelitis (ATM) is an acquired spinal cord disorder that presents with sudden-onset of varying degrees of motor weakness, sensory loss, and bowel and/or bladder dysfunction due to an immunological reaction, that could be supported by MRI findings [8]. The incidence of acute transverse myelitis is up to 3 per 100,000 patient years (0.003%) [9]. The etiology of ATM can vary from inflammatory, demyelinating, autoimmune, infectious, toxin-induced and paraneoplastic factors. According to a review article published in April 2021, ATM has proved to be a relatively common neurological complication of COVID-19, accounting for 1.2% of all COVID-19 neurological complications [10]. The Oxford-AstraZeneca COVID-19 vaccine consists of a replication-deficient chimpanzee adenoviral (ChAdOx1) containing SARS-CoV-2 structural surface vector glycoprotein antigen (spike protein) gene. Three vaccine-related ATM cases have been reported due to the Oxford-AstraZeneca COVID-19 vaccine [11,12].

The dormancy period between the time of infection with COVID-19 and developing ATM is unknown, especially since some patients have an asymptomatic infection course. In our cases, there were antecedent respiratory and systemic symptoms for almost four to five days while in the first reported case of ATM due to COVID-19 is a 66-year-old patient in China, neurological features presented on day 10 of respiratory symptoms [10].

The mechanism by which COVID-19 causes ATM is not completely understood but has been assumed to be similar to that of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) that arose in 2002 due to the structural resemblance of both RNA viruses. SARS-CoV-1 was thought to cause extra-pulmonary manifestations through its functional receptor, ACE-2, which is abundantly expressed on the endothelial layer of blood vessels of all organs. Entrance to the nervous system can take place through two pathways: either directly or indirectly. The direct pathway is through trans-synaptic transmission from the peripheral nervous system since neurons do not express the ACE-2 receptor themselves or by hematogenous spread into the blood-brain barrier (BBB) through ACE-2 [13]. On the other hand, the indirect pathway is through a systemic immune response that prompts the release of a cytokine storm, especially interleukin-6 (IL-6). Consequently, these proinflammatory cytokines increase the vascular permeability of the BBB and enhance the dissemination of the virus. Further, an exaggerated autoimmune cytokine response will likely induce incessant multiorgan failure and eventually the death of the patient [14]. This autoimmune theory has been also sustained by the positive patient response to steroids in one case report from Dubai [15]. However, in one of our cases, and two other reported cases in China and India, patients did not show satisfactory...
improvement in symptoms after receiving steroids, despite observing radiological amelioration in one of our patients particularly. Hence, consensus on whether the mechanism is direct viral neurotropism or an autoimmune has not been attained yet. In favor of the autoimmune theory, more research is required to explore immunomodulating treatments that allow for a balance between a forceful inflammatory response that is beneficial to encase the viral infection and an exaggerated cytokine response to avoid multigorgan involvement. Even though, interestingly, our patient’s baseline symptoms and lab results did not deteriorate after receiving several subsequent immune–modulating treatment modalities.

In the group of hospitalized patients with COVID-19 from three centers in China, it was reported that the development of neurological complications was significantly more in those patients with a severe infection status, occurring in 45.5% of them [1]. The severity of COVID-19 pneumonia was determined in concordance with the criteria set by the American Thoracic Society. Nonetheless, our patient was classified as having a non-severe infectious course as per the guidelines, yet developed ATM. In another study, Sahaka et al. suggested the use of IL-6 to predict the severity and need of hospitalization of COVID-19 confirmed patients due to its representation of the inflammatory state; however, we did not measure levels of IL-6 in our second case while in the first case it was high [16].

Another possible contributing factor to developing complications secondary to COVID-19 could be attributed to the patient’s vaccination status, since Thompson et al. found that the mean viral load in patients who were partially or full vaccinated was 40% less than those who were unvaccinated at all, like our patient [17].

Conclusions
This case series represents patients with COVID-19-associated acute transverse myelitis, a rare neurologic complication that was supported by abnormal MRI spinal cord and CSF findings. The exact mechanism of COVID-19-associated ATM is multifactorial and may arise from direct effects of the virus as well as a systemic response to SARS-CoV-2 infection. These cases show that we need to be vigilant of the neurological complications of COVID-19 infections and help physicians in the early diagnosis of rare COVID-19–associated acute transverse myelitis.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Medical Research Centre (MRC) issued approval 04-20-590. Entitled "COVID-19 Associated Acute Transverse Myelitis; A Rare Neurologic Condition. Case Series" has been approved by MRC, HMC, Qatar. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
Adnan Khan, Mohammad Alhatou, Osama Elalamy, Ghulam Adeli, Ahmed Mohammad, Naveed Akhtar, Khawaja Haroon, Suhail Hussain, Suha Elmaki, Yahya Imam, Mirza Baig.

References
1. Mao L, Jin H, Wang M, et al.: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77:683-90. 10.1001/jama.neurol.2020.1127
2. Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT, Chaillon A: Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020, 92:602-11. 10.1002/jmv.25731
3. Wan Y, Shang J, Graham R, Baric RS, Li F: Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020, 94: 10.1128/JVI.00127-20
4. Nemoto W, Yamagata R, Nakagawasai O, et al.: Effect of spinal angiotensin-converting enzyme 2 activation on the formalin-induced nociceptive response in mice. Eur J Pharmacol. 2020, 872:179250.
5. Yamagata R, Nemoto W, Fujita M, Nakagawasai O, Tan-No K: Angiotensin (1-7) attenuates the nociceptive behavior induced by substance P and NMDA via spinal MAS1. Biol Pharm Bull. 2021, 44:742-6.
6. Larvie M, Lev MI, Hess CP: More on neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020, 382:e110. 10.1056/NEJMec2015132
7. Nepal G, Rehrig IJH, Shrestha GS, et al.: Neurological manifestations of COVID-19: a systematic review. Crit Care. 2020, 24:421. 10.1186/s13054-020-03521-z
8. Greenberg BM, Krishnan C, Harder L: New onset transverse myelitis diagnostic accuracy and patient experiences. Mult Scler Relat Disord. 2019, 30:42-4. 10.1016/j.msard.2019.01.046
9. West TW, Hess C, Cree BA: Acute transverse myelitis: demyelinating, inflammatory, and infectious
myelopathies. Semin Neurol. 2012, 32:97-113. 10.1055/s-0032-1322586

10. Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D: Acute transverse myelitis (ATM): clinical review of 45 patients with COVID-19-associated ATM and 5 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021, 12:653786. 10.3389/fimmu.2021.653786

11. Voysey M, Clemens SA, Madhi SA, et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021, 397:99-111. 10.1016/S0140-6736(20)32661-1

12. Knoll MD, Wonodi C: Oxford–AstraZeneca COVID–19 vaccine efficacy. Lancet. 2021, 397:72-4. 10.1016/S0140-6736(20)32623-4

13. Hamming I, Timens W, Balbuijn ML, Lely AT, Navis G, van Goor H: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004, 203:631-7. 10.1002/path.1570

14. Chakraborty U, Chandra A, Ray AK, Biswas P: COVID-19-associated acute transverse myelitis: a rare entity. BMJ Case Rep. 2020, 13:

15. AlKetbi R, AlNuaimi D, AlMulla M, AlTalai N, Samir M, Kumar N, AlBastaki U: Acute myelitis as a neurological complication of Covid-19: a case report and MRI findings. Radiol Case Rep. 2020, 15:1591-5. 10.1016/j.radcr.2020.06.001

16. Sahaka P, Kočičálová A, Straka I, et al.: Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infect Dis. 2021, 21:308. 10.1186/s12879-021-05945-8

17. Thompson MG, Burgess JL, Naleway AL, et al.: Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021, 385:320-9. 10.1056/NEJMoa2107058